From a guideline perspective, WHO recommends oxytocin (in injectable form) as the uterotonic of choice to prevent PPH, and recommend other injectable uterotonics or oral misoprostol as alternatives when oxytocin is unavailable [13]. The gene discussed is OXT; the disease is pulmonary arterial hypertension.